The biopharma announced fiscal third-quarter 2019 operating results and multiple updates from the pipeline.
News & Analysis: Arrowhead Pharmaceuticals
Shares are trading hands at their highest level in years, and have posted a three-year return of over 350%.
There was plenty of pipeline progress for the clinical-stage biotech in the third quarter.
ARWR earnings call for the period ending June 30, 2019.
Could the second half of the year be as much fun as the first?
The biopharma company started several new clinical trials and enjoyed success in others since the start of the calendar year.
Here's how they could continue to climb.
The clinical-stage developer of RNAi therapies is being added to the S&P 600 index.
ARWR earnings call for the period ending March 31, 2019.
Investors cheered the news in a fiscal first-quarter 2019 earnings report.